Award

Mohw112-tdu-b-211-144002

Funder: Ministry of Health and Welfare

Funded outputs count: 13

Funder award ID: MOHW112-TDU-B-211-144002

OpenAlex ID: G4983179556

Adjuvant chemotherapy with or without targeted therapy for patients with resectable synchronous colon cancer and liver or lung-confined metastases: a nationwide Taiwanese database study

2026 · P.-Y. Chen, Y.-H. Liang, et al. · ESMO Gastrointestinal Oncology

Early Change in Subcutaneous Fat Attenuation on Follow-up CT Provides Prognostic Information Beyond AFP in Advanced Hepatocellular Carcinoma During Immunotherapy

2026 · Bang-Bin Chen, Chien-Huai Chuang, et al. · Academic Radiology

Long-term survival of patients who received atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma

2025 · Ching-Tso Chen, Yin-Hsun Feng, et al. · Journal of the Formosan Medical Association · 4

Impact of 10-year measles, mumps and rubella booster vaccination program among healthcare personnel: a cross-sectional study

2025 · Liang-En Hwang, Kuan-Yin Lin, et al. · Vaccine · 2

Effectiveness of full mRNA vaccinations to prevent COVID-19 among immunocompromised patients receiving tixagevimab-cilgavimab as pre-exposure prophylaxis–authors’ response

2025 · Pao-Yu Chen, Tzong-Yow Wu, et al. · Journal of the Formosan Medical Association

Effectiveness of full mRNA vaccinations to prevent COVID-19 among immunocompromised patients receiving tixagevimab-cilgavimab as pre-exposure prophylaxis

2025 · Pao-Yu Chen, Tzong-Yow Wu, et al. · Journal of the Formosan Medical Association · 2

Prompt initiation of durvalumab and tremelimumab for unresectable hepatocellular carcinoma in patients with chronic active hepatitis B: a phase 2 clinical trial

2025 · Yu-Yun Shao, Ching-Tso Chen, et al. · British Journal of Cancer · 10

Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2‐positive early breast cancer: A meta‐regression analysis

2024 · Ming‐Han Yang, Chiun‐Sheng Huang, et al. · Cancer Medicine · 4

Implication of genotypes for prognosis of Candida glabrata bloodstream infections

2024 · Pao-Yu Chen, Yu-Shan Huang, et al. · Journal of Antimicrobial Chemotherapy · 1

Changes in Posttreatment Spleen Volume Associated with Immunotherapy Outcomes for Advanced Hepatocellular Carcinoma

2024 · Bang-Bin Chen, Po-Chin Liang, et al. · Journal of Hepatocellular Carcinoma · 8

Sidedness and addition of chemotherapy associated with treatment outcomes of regorafenib for metastatic colorectal cancer: a population-wide cohort study

2024 · T.-C. Wu, Y.-H. Liang, et al. · ESMO Gastrointestinal Oncology · 2

Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients

2024 · Tzong-Yow Wu, Pao-Yu Chen, et al. · Journal of Antimicrobial Chemotherapy · 3

Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial)

2023 · Sung-Hsin Kuo, Ling-Ming Tseng, et al. · BMC Cancer · 5